These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3175422)

  • 1. [Aspirin and coronary heart disease].
    Dubach P
    Schweiz Rundsch Med Prax; 1988 Sep; 77(37):961-2. PubMed ID: 3175422
    [No Abstract]   [Full Text] [Related]  

  • 2. Can aspirin prevent recurrence of heart attacks and strokes?
    Kent S
    Geriatrics; 1982 Jan; 37(1):169-72. PubMed ID: 7033047
    [No Abstract]   [Full Text] [Related]  

  • 3. Aspirin and the risk of hemorrhagic stroke.
    Rosenberg R
    J Fam Pract; 1999 Mar; 48(3):169-70. PubMed ID: 10086752
    [No Abstract]   [Full Text] [Related]  

  • 4. Aspirin and ischaemic heart disease.
    Br J Hosp Med; 1986 Aug; 36(2):85. PubMed ID: 3527318
    [No Abstract]   [Full Text] [Related]  

  • 5. [Aspirin against aging? For whom and how much?].
    Oelz O; Meier PJ
    Ther Umsch; 1990 Aug; 47(8):648-52. PubMed ID: 2218966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary prevention of coronary heart disease with aspirin].
    Kübler W
    Z Kardiol; 2004; 93 Suppl 2():II33-6. PubMed ID: 15021994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction.
    Young FE; Nightingale SL; Temple RA
    JAMA; 1988 Jun; 259(21):3158-60. PubMed ID: 3367492
    [No Abstract]   [Full Text] [Related]  

  • 8. Controversies in cardiology. Proposed: low-dose aspirin should be taken daily after age 40 if total serum cholesterol is greater than 160.
    Schoenberger JA; Mann GV
    Hosp Pract (Off Ed); 1982 Dec; 17(12):50A, 50D, 50F passim. PubMed ID: 6815063
    [No Abstract]   [Full Text] [Related]  

  • 9. [Blood thinning in heart patients].
    Meier B
    Ther Umsch; 1995 Oct; 52(10):661-71. PubMed ID: 7482377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aspirin in the prevention and management of coronary artery disease].
    Cox RA
    Bol Asoc Med P R; 1990 Jun; 82(6):271-2. PubMed ID: 2222685
    [No Abstract]   [Full Text] [Related]  

  • 11. [Secondary prevention in chronic coronary heart disease].
    Hunziker P; Bertel O
    Schweiz Med Wochenschr; 1997 Feb; 127(7):254-60. PubMed ID: 9157530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study.
    Linos A; Worthington JW; O'Fallon W; Fuster V; Whisnant JP; Kurland LT
    Mayo Clin Proc; 1978 Sep; 53(9):581-6. PubMed ID: 682687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
    Mikkelsson J; Eskola M; Nikus K; Karhunen PJ; Niemela K
    Ann Med; 2008; 40(4):296-302. PubMed ID: 18428022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin for the primary prevention of coronary events.
    Mascitelli L; Pezzetta F
    N Engl J Med; 2002 Sep; 347(12):948; author reply 948. PubMed ID: 12240692
    [No Abstract]   [Full Text] [Related]  

  • 15. [Persantin and aspirin in coronary heart disease. The persantin-aspirin reinfarction study group (PARIS)].
    MMW Munch Med Wochenschr; 1980 Dec; 122(49):1761-71. PubMed ID: 6779148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
    Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
    Topol EJ; Easton D; Harrington RA; Amarenco P; Califf RM; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Granett J; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Sigmon K; Pieper K; Vallee M; Willerson JT;
    Circulation; 2003 Jul; 108(4):399-406. PubMed ID: 12874182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
    Genton E
    Circulation; 1980 Dec; 62(6 Pt 2):V111-21. PubMed ID: 6108166
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
    Cruz-Fernández JM; López-Bescós L; García-Dorado D; López García-Aranda V; Cabadés A; Martín-Jadraque L; Velasco JA; Castro-Beiras A; Torres F; Marfil F; Navarro E
    Eur Heart J; 2000 Mar; 21(6):457-65. PubMed ID: 10681486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin and secondary mortality after myocardial infarction.
    Elwood PC; Sweetnam PM
    Circulation; 1980 Dec; 62(6 Pt 2):V53-8. PubMed ID: 7438381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.